This is a prospective, observational study to establish the connection between periodontitis and BSI in AML patients planning to receive intensive chemotherapy.
Once eligibility is confirmed, participants will undergo a specialized baseline periodontal examination, gingival sulcus microbiota sampling and saliva sample at baseline before starting chemotherapy. Patients will be separated into 2 cohorts, with periodontitis (Arm A) and without periodontitis (Arm B). All patients will receive standard oncologic supportive care including antibiotic prophylaxis. Serum samples will be obtained at baseline, at the onset of neutropenic fever, and weekly until day 28 or discharge (whichever sooner). Study participation will continue during the duration of standard of care chemotherapy for 28 days or until discharge from hospital, whichever later.
Study Type
OBSERVATIONAL
Enrollment
3
standard oncologic supportive care including antibiotic prophylaxis
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Number of participants with Blood stream infections
Number of participants experiencing Blood stream infections (BSI) by day 28 of chemotherapy
Time frame: Day 28 of chemotherapy
Number of participants with Neutropenic fever
Number of participants experiencing Neutropenic fever (NF) by day 28 of chemotherapy
Time frame: Day 28 of chemotherapy
Number of participants exposed to different antibiotics
Number of participants with antibiotic exposure by day 28 of chemotherapy
Time frame: Day 28 of chemotherapy
Length of hospitalization
Number of days the patients were hospitalized
Time frame: Day 28 of chemotherapy
Number of participants who died
Number of participants who died by day 28 of chemotherapy
Time frame: Day 28 of chemotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.